Chronobiology and the treatment of rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 24, Issue 3, 2012, Pages 312-318

  Cutolo, Maurizio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

chronobiology; circadian rhythms; glucocorticoids; rheumatoid arthritis; sleep

Indexed keywords

METHOTREXATE; PREDNISONE;

BEDTIME DOSAGE; CHRONOTHERAPY; CIRCADIAN RHYTHM; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENERGY; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SYMPTOM; TIMED DRUG RELEASE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CIRCADIAN RHYTHM; CYTOKINES; DRUG CHRONOTHERAPY; ENERGY METABOLISM; GLUCOCORTICOIDS; HUMANS; SLEEP;

EID: 84859266040     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283521c78     Document Type: Review

References (36)

1. Cutolo M, Buttgereit F, Straub RH. Regulation of glucocorticoids by the central nervous system. Clin Exp Rheumatol 2011; 29 (5 Suppl 68):S19-S22.
2. Straub RH, Buttgereit F, Cutolo M. Alterations of the hypothalamic-pituitaryadrenal axis in systemic immune diseases: a role for misguided energy regulation. Clin Exp Rheumatol 2011; 29 (5 Suppl 68):S23-S31
3. Bang J, Chang HW, Jung HR, et al. Melatonin attenuates clock gene Cryptochrome1, which may aggravates mouse antitype II collagen antibody-induced arthritis. Rheumatol Int 2012;32:379-385.
4. Crofford LJ, Kalogeras KT,Mastorakos G, et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997; 82:1279-1283 (Pubitemid 27166676)
5. Cutolo M. Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat Rev Rheumatol 2011; 7:500-502
6. Chrousos GP. The hypothalamic-pituitaryadrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351-1362.
7. Kino T, Chrousos GP. Acetylation-mediated epigenetic regulation of glucocorticoid receptor activity: circadian rhythm-associated alterations of glucocorticoid actions in target tissues. Mol Cell Endocrinol 2011; 336:23-33.
8. Mullington JM, Haack M, Toth M, et al. Cardiovascular, inflammatory, and metabolic consequences of sleep deprivation. Prog Cardiovasc Dis 2009; 51:294-302.
9. Lange T, Dimitrov S, Born J. Effects of sleep and circadian rhythm on the human immune system. Ann N Y Acad Sci 2010; 1193:48-59.
10. Sierakowski S, Cutolo M. Morning symptoms in rheumatoid arthritis: a defining characteristic and marker of active disease. Scand J Rheumatol Suppl 2011; 125:1-5
11. Cutolo M, Straub RH, Bijlsma JW. Neuroendocrine-immune interactions in synovitis. Nat Clin Pract Rheumatol 2007; 3:627-634.
12. McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010; 69:1898-1906.
13. Straub RH, Cutolo M. Rheumatology. 5th ed.: In: Hochberg MC, Silman AJ, Smolen JS, Michael E Weinblatt MD, and Michael H Weisman MD (editors). Effects of the neuroendocrine system on development and function of the immune system. Elsevier; 2010
14. Bollinger T, Bollinger A, Naujoks J, et al. The influence of regulatory T cells and diurnal hormone rhythms on T helper cell activity. Immunology 2010; 131:488-500
15. Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum 2007; 56:399-408
16. Straub RH, Cutolo M, Buttgereit F, Pongratz G. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med 2010; 267:543-560.
17. Straub RH. Concepts of evolutionary medicine and energy regulation contribute to the etiology of systemic chronic inflammatory diseases. Brain Behav Immun 2011; 25:1-5.
18. Buttgereit F, Burmester GR, Straub RH, et al. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011; 63:1-9
19. Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69:1010-1014.
20. van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010; 69:1913-1919.
21. Cutolo M, Seriolo B, Craviotto C, et al. Circadian rhythms in RA. Ann Rheum Dis 2003; 62:593-596. (Pubitemid 36760552)
22. Cutolo M, Otsa K, Aakre O, Sulli A. Nocturnal hormones and clinical rhythms in rheumatoid arthritis. Ann N Y Acad Sci 2005; 1051:372-381. (Pubitemid 41362767)
23. Jacobs JW, Bijlsma JW. Modified release prednisone in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69:1257-1259
24. Spies CM, Cutolo M, Straub RH, et al. Prednisone chronotherapy. Clin Exp Rheumatol 2011; 29 (5 Suppl 68):S42-S45.
25. Alten R, Döring G, Cutolo M, et al. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol 2010; 37:2025-2031
26. Buttgereit F, Doering G, Shaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008; 371:205-214
27. Buttgereit F, Doering G, Schaeffler A, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis 2010; 69:1275-1280
28. Kirwan JR, Clarke L, Hunt LP, et al. Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis. Ann N Y Acad Sci 2010; 1193:127-133
29. Smolen JS, LandewéR, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964-975.
30. To H, Irie S, Tomonari M, et al. Therapeutic index of methotrexate depends on circadian cycling of tumour necrosis factor-alpha in collageninduced arthritic rats and mice. J Pharm Pharmacol 2009; 61:1333-1338
31. To H, Yoshimatsu H, Tomonari M, Ida H, et al. Methotrexate chronotherapy is effective against rheumatoid arthritis. Chronobiol Int 2011; 28:267-274.
32. Spies CM, Cutolo M, Straub RH, et al. More night than day-circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis. J Rheumatol 2010; 37:894-899
33. Cutolo M, Straub RH. Polymyalgia rheumatica: evidence for a hypothalamicpituitary-adrenal axis-driven disease. Clin Exp Rheumatol 2000; 18:655-658.
34. Cutolo M, Straub RH, Foppiani L, et al. Adrenal gland hypofunction in active polymyalgia rheumatica. Effect of glucocorticoid treatment on adrenal hormones and interleukin 6. J Rheumatol 2002; 29:748-756. (Pubitemid 34303869)
35. Caporali R, Cimmino MA, Montecucco C, Cutolo M. Glucocorticoid treatment of polymyalgia rheumatica. Clin Exp Rheumatol 2011; 29 (5 Suppl 68): S143-S147.
36. Debbono M, Ross RJ. Optimal glucocorticoid therapy. Endocr Dev 2011; 20:173-180.